Base de dados : MEDLINE
Pesquisa : C20.683 [Categoria DeCS]
Referências encontradas : 84 [refinar]
Mostrando: 1 .. 10   no formato [Detalhado]

página 1 de 9 ir para página                      

  1 / 84 MEDLINE  
              next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:28252625
[Au] Autor:Rekhtina IG; Mendeleeva LP; Biryukova LS
[Ad] Endereço:National Research Center for Hematology, Ministry of Health of Russia, Moscow, Russia.
[Ti] Título:[Light-chain deposition disease is a hematologic problem].
[Ti] Título:Bolezn' depozitov legkikh tsepei ­ gematologicheskaia problema..
[So] Source:Ter Arkh;89(1):38-42, 2017.
[Is] ISSN:0040-3660
[Cp] País de publicação:Russia (Federation)
[La] Idioma:rus
[Ab] Resumo:AIM: To analyze clinical and laboratory data and treatment results in patients with light-chain deposition disease (LCDD). SUBJECTS AND METHODS: Nine patients with LCDD and kidney injury were examined. The diagnosis was based on the results of light and immunofluorescence microscopy of renal biopsy specimens. All the patients received bortezomib, cyclophosphamide, and dexamethasone (VCD) induction therapy. RESULTS: Six patients were diagnosed with multiple myeloma; in 3 patients LCDD was considered within monoclonal gammopathy manly involving the kidney. By the initiation of therapy, all the patients were diagnosed as having chronic kidney disease (Stage III (n=2), Stage IV (n=2), and dialysis-related renal failure (n=5)). After the VCD treatment, 7 of 9 patients achieved a hematologic response. Second-line therapy with lenalidomide proved to be effective in the other 2 cases. Five patients achieved complete remission; 3 had a very good partial remission. Thereafter, 2 patients received high-dose melphalan chemotherapy and autologous hematopoietic stem cell transplantation. Better renal function was noted in only 2 cases. CONCLUSION: Despite the high efficiency of therapy aimed to reduce monoclonal light chains; improved renal function was observed in only 2 (22%) patients. Such low rates of a renal response were due to the late initiation of therapy.
[Mh] Termos MeSH primário: Doenças Hematológicas/diagnóstico
Transtornos Imunoproliferativos/diagnóstico
Plasmócitos
Insuficiência Renal Crônica/diagnóstico
[Mh] Termos MeSH secundário: Idoso
Feminino
Doenças Hematológicas/complicações
Doenças Hematológicas/tratamento farmacológico
Seres Humanos
Transtornos Imunoproliferativos/complicações
Transtornos Imunoproliferativos/tratamento farmacológico
Masculino
Meia-Idade
Insuficiência Renal Crônica/etiologia
[Pt] Tipo de publicação:JOURNAL ARTICLE
[Em] Mês de entrada:1706
[Cu] Atualização por classe:170621
[Lr] Data última revisão:
170621
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:170303
[St] Status:MEDLINE
[do] DOI:10.17116/terarkh201789138-42


  2 / 84 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:26510488
[Au] Autor:Lee SK; Kim JY; Han AR; Hur SE; Kim CJ; Kim TH; Cho BR; Han JW; Han SG; Na BJ; Kwak-Kim J
[Ad] Endereço:Department of Obstetrics and Gynecology, Konyang University Hospital, Daejeon, Korea.
[Ti] Título:Intravenous Immunoglobulin G Improves Pregnancy Outcome in Women with Recurrent Pregnancy Losses with Cellular Immune Abnormalities.
[So] Source:Am J Reprod Immunol;75(1):59-68, 2016 Jan.
[Is] ISSN:1600-0897
[Cp] País de publicação:Denmark
[La] Idioma:eng
[Ab] Resumo:PROBLEM: We investigated the therapeutic effect of intravenous immunoglobulin (IVIG) in women with recurrent pregnancy loss (RPL). METHOD OF STUDY: This was a retrospective observational study. Total 189 RPL women who experienced ≥2 miscarriages were enrolled and investigated conventional etiologies, thrombophilia, and cellular immunity. Patients were divided into four groups; known etiology with (Gr1) and without cellular immune abnormality (Gr2), unknown etiology with (Gr3) and without cellular immune abnormality (Gr4). IVIG was administrated from early pregnancy to 30 weeks of gestation to women with cellular immune abnormality (Gr1 + Gr3). RESULTS: Cellular immune abnormalities (increased level or cytotoxicity of NK cells and Th1/Th2 ratio) were present in 111 of 189 RPL women (58.7%). Live birth rates of women with and without cellular immune abnormality were not different (Gr1 + Gr3, 84.8% versus Gr2 + Gr4, 89.7%). Furthermore, IVIG success rates were the same between Gr1 and Gr3, those who had cellular immune abnormality. Nevertheless lack of an appropriate control in this study, our IVIG outcome demonstrated better live birth rate compared with those of other investigators. CONCLUSION: Treatment modalities stratified by underlying etiologies of RPL may improve pregnancy outcome. Administration of IVIG is likely to have clinical efficacy in RPL women with cellular immune abnormality.
[Mh] Termos MeSH primário: Aborto Habitual/terapia
Imunoglobulinas Intravenosas/administração & dosagem
Transtornos Imunoproliferativos/terapia
Imunoterapia/métodos
Células Matadoras Naturais/imunologia
[Mh] Termos MeSH secundário: Aborto Habitual/imunologia
Adulto
Citotoxicidade Imunológica
Feminino
Seguimentos
Seres Humanos
Imunidade Celular
Imunoglobulinas Intravenosas/efeitos adversos
Transtornos Imunoproliferativos/complicações
Transtornos Imunoproliferativos/imunologia
Gravidez
Taxa de Gravidez
Estudos Retrospectivos
Resultado do Tratamento
[Pt] Tipo de publicação:JOURNAL ARTICLE; OBSERVATIONAL STUDY; RESEARCH SUPPORT, NON-U.S. GOV'T
[Nm] Nome de substância:
0 (Immunoglobulins, Intravenous)
[Em] Mês de entrada:1610
[Cu] Atualização por classe:161230
[Lr] Data última revisão:
161230
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:151030
[St] Status:MEDLINE
[do] DOI:10.1111/aji.12442


  3 / 84 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:25931583
[Au] Autor:Kramer NJ; Wang WL; Reyes EY; Kumar B; Chen CC; Ramakrishna C; Cantin EM; Vonderfecht SL; Taganov KD; Chau N; Boldin MP
[Ad] Endereço:Department of Molecular and Cellular Biology.
[Ti] Título:Altered lymphopoiesis and immunodeficiency in miR-142 null mice.
[So] Source:Blood;125(24):3720-30, 2015 Jun 11.
[Is] ISSN:1528-0020
[Cp] País de publicação:United States
[La] Idioma:eng
[Ab] Resumo:MicroRNAs (miRNAs) are a class of powerful posttranscriptional regulators implicated in the control of diverse biological processes, including regulation of hematopoiesis and the immune response. To define the biological functions of miR-142, which is preferentially and abundantly expressed in immune cells, we created a mouse line with a targeted deletion of this gene. Our analysis of miR-142(-/-) mice revealed a critical role for this miRNA in the development and homeostasis of lymphocytes. Marginal zone B cells expand in the knockout spleen, whereas the number of T and B1 B cells in the periphery is reduced. Abnormal development of hematopoietic lineages in miR-142(-/-) animals is accompanied by a profound immunodeficiency, manifested by hypoimmunoglobulinemia and failure to mount a productive immune response to soluble antigens and virus. miR-142(-/-) B cells express elevated levels of B-cell-activating factor (BAFF) receptor (BAFF-R) and as a result proliferate more robustly in response to BAFF stimulation. Lowering the BAFF-R gene dose in miR-142(-/-) mice rescues the B-cell expansion defect, suggesting that BAFF-R is a bona fide miR-142 target through which it controls B-cell homeostasis. Collectively, our results uncover miR-142 as an essential regulator of lymphopoiesis, and suggest that lesions in this miRNA gene may lead to primary immunodeficiency.
[Mh] Termos MeSH primário: Linfócitos B/patologia
Deleção de Genes
Síndromes de Imunodeficiência/genética
Transtornos Imunoproliferativos/genética
Linfopoese
MicroRNAs/genética
[Mh] Termos MeSH secundário: Animais
Receptor do Fator Ativador de Células B/genética
Linfócitos B/imunologia
Linfócitos B/metabolismo
Feminino
Regulação da Expressão Gênica
Técnicas de Inativação de Genes
Imunidade Celular
Imunidade Humoral
Síndromes de Imunodeficiência/imunologia
Síndromes de Imunodeficiência/patologia
Transtornos Imunoproliferativos/imunologia
Transtornos Imunoproliferativos/patologia
Masculino
Camundongos
Camundongos Endogâmicos C57BL
MicroRNAs/imunologia
[Pt] Tipo de publicação:JOURNAL ARTICLE
[Nm] Nome de substância:
0 (B-Cell Activation Factor Receptor); 0 (MicroRNAs); 0 (Mirn142 microRNA, mouse); 0 (Tnfrsf13c protein, mouse)
[Em] Mês de entrada:1508
[Cu] Atualização por classe:150613
[Lr] Data última revisão:
150613
[Sb] Subgrupo de revista:AIM; IM
[Da] Data de entrada para processamento:150502
[St] Status:MEDLINE
[do] DOI:10.1182/blood-2014-10-603951


  4 / 84 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
PubMed Central Texto completo
Texto completo
[PMID]:24534189
[Au] Autor:Wang JQ; Jeelall YS; Beutler B; Horikawa K; Goodnow CC
[Ad] Endereço:Department of Immunology, John Curtin School of Medical Research, 2 Australian Phenomics Facility, The Australian National University, Canberra, Australian Capital Territory 0200, Australia.
[Ti] Título:Consequences of the recurrent MYD88(L265P) somatic mutation for B cell tolerance.
[So] Source:J Exp Med;211(3):413-26, 2014 Mar 10.
[Is] ISSN:1540-9538
[Cp] País de publicação:United States
[La] Idioma:eng
[Ab] Resumo:MYD88(L265P) has recently been discovered as an extraordinarily frequent somatic mutation in benign monoclonal IgM gammopathy, Waldenström's macroglobulinemia, and diffuse large B cell lymphoma. In this study, we analyze the consequences for antigen-activated primary B cells of acquiring MYD88(L265P). The mutation induced rapid B cell division in the absence of exogenous TLR ligands and was inhibited by Unc93b1(3d) mutation and chloroquine or TLR9 deficiency, indicating continued dependence on upstream TLR9 activation. Proliferation and NF-κB activation induced by MYD88(L265P) were nevertheless rapidly countered by the induction of TNFAIP3, an NF-κB inhibitor frequently inactivated in MYD88(L265P)-bearing lymphomas, and extinguished by Bim-dependent apoptosis. MYD88(L265P) caused self-reactive B cells to accumulate in vivo only when apoptosis was opposed by Bcl2 overexpression. These results reveal checkpoints that fortify TLR responses against aberrant B cell proliferation in response to ubiquitous TLR and BCR self-ligands and suggest that tolerance failure requires the accumulation of multiple somatic mutations.
[Mh] Termos MeSH primário: Linfócitos B/metabolismo
Regulação da Expressão Gênica/imunologia
Tolerância Imunológica/genética
Transtornos Imunoproliferativos/genética
Fator 88 de Diferenciação Mieloide/genética
[Mh] Termos MeSH secundário: Transferência Adotiva
Animais
Apoptose/imunologia
Linfócitos B/imunologia
Western Blotting
Divisão Celular/imunologia
Proliferação Celular
Cisteína Endopeptidases/metabolismo
Rearranjo Gênico do Linfócito B/genética
Peptídeos e Proteínas de Sinalização Intracelular/metabolismo
Camundongos
Camundongos Endogâmicos C57BL
Camundongos Transgênicos
Mutação de Sentido Incorreto/genética
NF-kappa B/metabolismo
Regiões Promotoras Genéticas/genética
Proteínas Proto-Oncogênicas c-bcl-2/imunologia
Proteínas Proto-Oncogênicas c-vav/genética
Proteína 3 Induzida por Fator de Necrose Tumoral alfa
[Pt] Tipo de publicação:JOURNAL ARTICLE; RESEARCH SUPPORT, N.I.H., EXTRAMURAL; RESEARCH SUPPORT, NON-U.S. GOV'T
[Nm] Nome de substância:
0 (Intracellular Signaling Peptides and Proteins); 0 (Myd88 protein, mouse); 0 (Myeloid Differentiation Factor 88); 0 (NF-kappa B); 0 (Proto-Oncogene Proteins c-bcl-2); 0 (Proto-Oncogene Proteins c-vav); 0 (Vav1 protein, mouse); 114100-40-2 (Bcl2 protein, mouse); EC 3.4.19.12 (Tumor Necrosis Factor alpha-Induced Protein 3); EC 3.4.22.- (Cysteine Endopeptidases); EC 3.4.22.- (Tnfaip3 protein, mouse)
[Em] Mês de entrada:1405
[Cu] Atualização por classe:170220
[Lr] Data última revisão:
170220
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:140219
[St] Status:MEDLINE
[do] DOI:10.1084/jem.20131424


  5 / 84 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:24370946
[Au] Autor:Bhagat M; Sehra ST; Shahane A; Kwan M
[Ad] Endereço:Division of Pulmonary, Allergy, and Critical Care, Department of Internal Medicine, University of Pennsylvania, Philadelphia, PA, USA.
[Ti] Título:Utility of immunologic testing in suspected rheumatologic disease.
[So] Source:Curr Allergy Asthma Rep;14(1):405, 2014 Jan.
[Is] ISSN:1534-6315
[Cp] País de publicação:United States
[La] Idioma:eng
[Ab] Resumo:The use of diagnostic testing in the clinical practice of medicine has been a shifting landscape from the time that the first blood test was utilized. This is no different in the field of immunology and in particular rheumatology. As the field of immunology is relatively young, the clinical tests are not well established and therefore guidelines for use are still under debate. In this review, we seek to look at some of the key autoantibodies, as well as other tests that are available to diagnose suspected rheumatologic disease, and examine how to best use these tests in the clinic. In particular, we will focus on the anti-nuclear antibodies, anti-neutrophil cytoplasmic antibodies, complement, cryoglobulins, rheumatoid factor, and anti-citrullinated protein antibodies.
[Mh] Termos MeSH primário: Autoanticorpos/sangue
Doenças Autoimunes/diagnóstico
Doenças Autoimunes/imunologia
Doenças Reumáticas/diagnóstico
Doenças Reumáticas/imunologia
Fator Reumatoide/sangue
[Mh] Termos MeSH secundário: Anticorpos Anticitoplasma de Neutrófilos/sangue
Anticorpos Anticitoplasma de Neutrófilos/imunologia
Anticorpos Antinucleares/sangue
Anticorpos Antinucleares/imunologia
Fatores Biológicos/sangue
Proteínas do Sistema Complemento/análise
Proteínas do Sistema Complemento/imunologia
Crioglobulinas/análise
Crioglobulinas/imunologia
Diagnóstico Diferencial
Seres Humanos
Testes Imunológicos
Transtornos Imunoproliferativos/diagnóstico
Transtornos Imunoproliferativos/imunologia
Sensibilidade e Especificidade
Urticária/diagnóstico
Urticária/imunologia
Vasculite/diagnóstico
Vasculite/imunologia
[Pt] Tipo de publicação:JOURNAL ARTICLE; REVIEW
[Nm] Nome de substância:
0 (Antibodies, Antineutrophil Cytoplasmic); 0 (Antibodies, Antinuclear); 0 (Autoantibodies); 0 (Biological Factors); 0 (Cryoglobulins); 9007-36-7 (Complement System Proteins); 9009-79-4 (Rheumatoid Factor)
[Em] Mês de entrada:1402
[Cu] Atualização por classe:171105
[Lr] Data última revisão:
171105
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:131228
[St] Status:MEDLINE
[do] DOI:10.1007/s11882-013-0405-5


  6 / 84 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:24361990
[Au] Autor:Aksungar FB; Ayer M; Serteser M; Coskun A; Unsal I
[Ad] Endereço:Department of Biochemistry, Acibadem Labmed Clinical Laboratories, Istanbul, Turkey Department of Biochemistry, Acibadem University School of Medicine, Istanbul, Turkey fehime.aksungar@acibademlabmed.com.tr.
[Ti] Título:A triclonal gammopathy in a relapsing multiple myeloma patient, detected by immunosubtraction method.
[So] Source:Ann Clin Biochem;51(Pt 5):606-10, 2014 Sep.
[Is] ISSN:1758-1001
[Cp] País de publicação:England
[La] Idioma:eng
[Ab] Resumo:Multiple myeloma (MM) is a plasma cell dyscrasia characterized by the malignant proliferation of a plasma cell clone that produces a monoclonal immunoglobulin. Diagnosis and management of patients with monoclonal gammopathies depend on accurate identification and characterization of monoclonal proteins. We present a 67-year-old male patient with anaemia, weakness and weight loss for six months. His physical examination was normal with no fever, and no bone lesions were present in the imaging studies. Laboratory investigations revealed low haemoglobin and albumin concentrations with high total protein and beta 2-microglobulin concentrations. Capillary zone electrophoresis with immunosubtraction method revealed a triclonal pattern of M-protein (IgG κ + IgG λ + IgA κ) which was not prominent with immunofixation electrophoresis. After bone marrow biopsy, MM with triclonal gammopathy was diagnosed and autologous stem cell transplantation was performed. Six months later, again a triclonal M-protein was detected by immunosubtraction method, and a relapse was confirmed with a second bone marrow biopsy. The occurrence of monoclonal and biclonal gammopathies can often be seen upon diagnosis in plasma cell dyscrasias and lymphoproliferative disorders, but triclonal paraproteins are very rare and their clinical significance is unknown. In this particular patient, triclonality was detected by an alternative method called immunosubtraction by capillary electrophoresis. The patient was resistant to therapy suggesting that more than one monoclonal M protein may be a negative prognostic factor, and with new technologies and methods, the number of patients with different monoclonal patterns may increase.
[Mh] Termos MeSH primário: Eletroforese Capilar/métodos
Imunoquímica/métodos
Transtornos Imunoproliferativos/sangue
Mieloma Múltiplo/patologia
[Mh] Termos MeSH secundário: Idoso
Transplante de Células-Tronco Hematopoéticas
Seres Humanos
Imunoglobulina A/sangue
Imunoglobulina G/sangue
Imunoglobulina M/sangue
Transtornos Imunoproliferativos/diagnóstico
Transtornos Imunoproliferativos/terapia
Masculino
Mieloma Múltiplo/sangue
Mieloma Múltiplo/complicações
Transplante Autólogo
[Pt] Tipo de publicação:CASE REPORTS; JOURNAL ARTICLE
[Nm] Nome de substância:
0 (Immunoglobulin A); 0 (Immunoglobulin G); 0 (Immunoglobulin M)
[Em] Mês de entrada:1505
[Cu] Atualização por classe:140816
[Lr] Data última revisão:
140816
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:131224
[St] Status:MEDLINE
[do] DOI:10.1177/0004563213512801


  7 / 84 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:24048848
[Au] Autor:Boulware MI; Heisler JD; Frick KM
[Ad] Endereço:Department of Psychology, University of Wisconsin-Milwaukee, Milwaukee, Wisconsin 53211.
[Ti] Título:The memory-enhancing effects of hippocampal estrogen receptor activation involve metabotropic glutamate receptor signaling.
[So] Source:J Neurosci;33(38):15184-94, 2013 Sep 18.
[Is] ISSN:1529-2401
[Cp] País de publicação:United States
[La] Idioma:eng
[Ab] Resumo:Our laboratory has demonstrated that 17ß-estradiol (E2) enhances hippocampal memory consolidation via rapid activation of multiple intracellular signaling cascades, including the ERK/MAPK cascade (Fernandez et al., 2008; Fan et al., 2010). However, the receptor mechanisms responsible for these effects of E2 remain unclear. In vitro, estrogen receptor α (ERα) signaling through metabotropic glutamate receptor 1a (mGluR1a) leads to ERK-dependent CREB phosphorylation (Boulware et al., 2005), suggesting that interactions between ERs and mGluR1a may be vital to the memory-enhancing effects of E2. As such, the present study tested the roles of classical estrogen receptors (ERα and ERß) and mGluR1a in mediating the effects of E2 on hippocampal memory consolidation. Dorsal hippocampal (DH) infusion of ERα (PPT) or ERß (DPN) agonists enhanced novel object recognition and object placement memory in ovariectomized female mice in an ERK-dependent manner, suggesting that these receptors influence memory by rapidly activating hippocampal cell signaling. Next, DH infusion of the mGluR1a antagonist LY367385 blocked the object and spatial memory facilitation induced by E2, PPT, and DPN, demonstrating that ER/mGluR1a signaling is critical for the memory-enhancing effects of E2. Finally, we show that ERα, ERß, mGluR1, and ERK all reside within specialized membrane microdomains of the DH, and that ERα and ERß physically interact with mGluR1, providing a means through which ERs may activate mGluRs and downstream signaling. Together, these findings provide the first in vivo evidence demonstrating that ER/mGluR signaling can mediate the beneficial effects of E2 on hippocampal memory consolidation.
[Mh] Termos MeSH primário: Hipocampo/metabolismo
Memória/fisiologia
Receptores Estrogênicos/metabolismo
Transdução de Sinais/fisiologia
[Mh] Termos MeSH secundário: Análise de Variância
Animais
Benzoatos/farmacologia
Caveolina 1/metabolismo
Ciclodextrinas/farmacologia
Relação Dose-Resposta a Droga
Inibidores Enzimáticos/farmacologia
Antagonistas de Aminoácidos Excitatórios/farmacologia
Comportamento Exploratório/efeitos dos fármacos
Feminino
Glicina/análogos & derivados
Glicina/farmacologia
Hipocampo/efeitos dos fármacos
Imunoprecipitação
Transtornos Imunoproliferativos
Infusões Intraventriculares
Memória/efeitos dos fármacos
Camundongos
Camundongos Endogâmicos C57BL
Nitrilos/farmacologia
Fenóis
Fosforilação/efeitos dos fármacos
Pirazóis/farmacologia
Transdução de Sinais/efeitos dos fármacos
[Pt] Tipo de publicação:JOURNAL ARTICLE; RESEARCH SUPPORT, NON-U.S. GOV'T
[Nm] Nome de substância:
0 (2,3-bis(4-hydroxyphenyl)-propionitrile); 0 (Benzoates); 0 (Cav1 protein, mouse); 0 (Caveolin 1); 0 (Cyclodextrins); 0 (Enzyme Inhibitors); 0 (Excitatory Amino Acid Antagonists); 0 (Nitriles); 0 (Phenols); 0 (Pyrazoles); 0 (Receptors, Estrogen); 0T83Y6JZPF (1,3,5-tris(4-hydroxyphenyl)-4-propyl-1H-pyrazole); 146669-29-6 (alpha-methyl-4-carboxyphenylglycine); TE7660XO1C (Glycine)
[Em] Mês de entrada:1311
[Cu] Atualização por classe:161125
[Lr] Data última revisão:
161125
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:130920
[St] Status:MEDLINE
[do] DOI:10.1523/JNEUROSCI.1716-13.2013


  8 / 84 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:23089073
[Au] Autor:Mino Y; Naito T; Watanabe T; Yamada T; Yagi T; Yamada H; Kawakami J
[Ad] Endereço:Department of Hospital Pharmacy, Hamamatsu University School of Medicine, 1-20-1 Handayama, Higashi-ku, Hamamatsu, Shizuoka 431-3192, Japan.
[Ti] Título:Hydroxy-itraconazole pharmacokinetics is similar to that of itraconazole in immunocompromised patients receiving oral solution of itraconazole.
[So] Source:Clin Chim Acta;415:128-32, 2013 Jan 16.
[Is] ISSN:1873-3492
[Cp] País de publicação:Netherlands
[La] Idioma:eng
[Ab] Resumo:BACKGROUND: The pharmacokinetic variability of hydroxy-itraconazole (OH-ITZ), an active metabolite of itraconazole (ITZ), is not fully known. METHODS: Oral solution of ITZ was administered in 46 immunocompromised patients as a single 200 mg dose for at least 12 days. The plasma concentrations of ITZ, active OH-ITZ, and keto-itraconazole (keto-ITZ), an inactive metabolite, 12 h after administration were determined by LC-UV or LC-MS/MS. RESULTS: The mean±SD of plasma concentrations of ITZ, OH-ITZ, and keto-ITZ were 833±468, 798±454, and 3.94±2.68 µg/l, respectively. A greater correlation coefficient was observed between plasma concentrations of ITZ and OH-ITZ (r=0.90, P<0.01) than between OH-ITZ and keto-ITZ (r=0.44, P<0.01). Plasma concentration of OH-ITZ was inversely correlated with concentration ratio of keto-ITZ to OH-ITZ (r=-0.52, P<0.01). Plasma concentrations of ITZ and OH-ITZ were correlated with serum concentration of albumin (r=0.36, P=0.01 and r=0.37, P=0.01) and estimated glomerular filtration rate (r=-0.27, P=0.08 and r=-0.35, P=0.02). CONCLUSIONS: The pharmacokinetic variability of OH-ITZ was associated with saturated metabolism to keto-ITZ, serum concentration of albumin, and renal function in immunocompromised patients. The plasma concentration of OH-ITZ was strongly correlated with that of ITZ. Prevention of fungal infections can be improved by determining the plasma concentration of ITZ or OH-ITZ.
[Mh] Termos MeSH primário: Antifúngicos/farmacocinética
Neoplasias Hematológicas/imunologia
Hospedeiro Imunocomprometido
Transtornos Imunoproliferativos/imunologia
Itraconazol/farmacocinética
Micoses/prevenção & controle
[Mh] Termos MeSH secundário: Administração Oral
Idoso
Antifúngicos/sangue
Cromatografia Líquida
Esquema de Medicação
Feminino
Taxa de Filtração Glomerular
Neoplasias Hematológicas/sangue
Neoplasias Hematológicas/tratamento farmacológico
Neoplasias Hematológicas/microbiologia
Seres Humanos
Transtornos Imunoproliferativos/sangue
Transtornos Imunoproliferativos/tratamento farmacológico
Transtornos Imunoproliferativos/microbiologia
Itraconazol/análogos & derivados
Itraconazol/sangue
Masculino
Meia-Idade
Albumina Sérica/análise
Soluções
Espectrometria de Massas em Tandem
[Pt] Tipo de publicação:JOURNAL ARTICLE
[Nm] Nome de substância:
0 (Antifungal Agents); 0 (Serum Albumin); 0 (Solutions); 304NUG5GF4 (Itraconazole)
[Em] Mês de entrada:1305
[Cu] Atualização por classe:131121
[Lr] Data última revisão:
131121
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:121024
[St] Status:MEDLINE


  9 / 84 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:23161721
[Au] Autor:Olteanu H; Harrington AM; Kroft SH
[Ad] Endereço:Dept of Pathology, Medical College of Wisconsin, Milwaukee, WI 53226, USA. holteanu@mcw.edu
[Ti] Título:CD200 expression in plasma cells of nonmyeloma immunoproliferative disorders: clinicopathologic features and comparison with plasma cell myeloma.
[So] Source:Am J Clin Pathol;138(6):867-76, 2012 Dec.
[Is] ISSN:1943-7722
[Cp] País de publicação:England
[La] Idioma:eng
[Ab] Resumo:The majority of plasma cell myelomas (PCMs) are positive for CD200, a membrane protein with immunosuppressive function. There are no flow cytometry data in the literature on plasma cell CD200 expression in other immunoproliferative disorders. Therefore we used flow cytometry to study the expression of CD200 on plasma cells in diagnostic bone marrow aspirates from 61 patients with monoclonal gammopathy of undetermined significance (MGUS) and 10 patients with lymphoplasmacytic lymphoma (LPL). For comparison, we evaluated CD200 expression in 74 PCM bone marrow biopsies. Thirty-three (54.1%) of 61 MGUS cases and 2 (20.0%) of 10 LPL cases were CD200+. Comparative clinicopathologic parameters for MGUS cases, based on CD200 expression status, showed no differences between the 2 groups. The proportion of CD200+ PCMs (73.0%) in our series was significantly higher than that of CD200+ MGUS (P = .030) and CD200+ LPL (P = .002) cases.
[Mh] Termos MeSH primário: Antígenos CD/metabolismo
Transtornos Imunoproliferativos/imunologia
Mieloma Múltiplo/imunologia
Plasmócitos/imunologia
[Mh] Termos MeSH secundário: Adulto
Idoso
Idoso de 80 Anos ou mais
Medula Óssea/imunologia
Medula Óssea/metabolismo
Medula Óssea/patologia
Feminino
Citometria de Fluxo
Seres Humanos
Imunofenotipagem
Transtornos Imunoproliferativos/metabolismo
Transtornos Imunoproliferativos/patologia
Masculino
Meia-Idade
Gamopatia Monoclonal de Significância Indeterminada/imunologia
Gamopatia Monoclonal de Significância Indeterminada/metabolismo
Gamopatia Monoclonal de Significância Indeterminada/patologia
Mieloma Múltiplo/metabolismo
Mieloma Múltiplo/patologia
Plasmócitos/metabolismo
Plasmócitos/patologia
Macroglobulinemia de Waldenstrom/imunologia
Macroglobulinemia de Waldenstrom/metabolismo
Macroglobulinemia de Waldenstrom/patologia
[Pt] Tipo de publicação:JOURNAL ARTICLE
[Nm] Nome de substância:
0 (Antigens, CD); 0 (antigens, CD200)
[Em] Mês de entrada:1301
[Cu] Atualização por classe:121119
[Lr] Data última revisão:
121119
[Sb] Subgrupo de revista:AIM; IM
[Da] Data de entrada para processamento:121120
[St] Status:MEDLINE
[do] DOI:10.1309/AJCP3TQR1TFHHGAS


  10 / 84 MEDLINE  
              first record previous record
seleciona
para imprimir
Fotocópia
PubMed Central Texto completo
Texto completo
[PMID]:22919404
[Au] Autor:Ko HM; Hernandez-Prera JC; Zhu H; Dikman SH; Sidhu HK; Ward SC; Thung SN
[Ad] Endereço:The Lillian and Henry M. Stratton-Hans Popper Department of Pathology, Mount Sinai School of Medicine, New York, NY 10029, USA. mabel.ko@mssm.edu
[Ti] Título:Morphologic features of extrahepatic manifestations of hepatitis C virus infection.
[So] Source:Clin Dev Immunol;2012:740138, 2012.
[Is] ISSN:1740-2530
[Cp] País de publicação:Egypt
[La] Idioma:eng
[Ab] Resumo:Cirrhosis and hepatocellular carcinoma are the prototypic complications of chronic hepatitis C virus infection in the liver. However, hepatitis C virus also affects a variety of other organs that may lead to significant morbidity and mortality. Extrahepatic manifestations of hepatitis C infection include a multitude of disease processes affecting the small vessels, skin, kidneys, salivary gland, eyes, thyroid, and immunologic system. The majority of these conditions are thought to be immune mediated. The most documented of these entities is mixed cryoglobulinemia. Morphologically, immune complex depositions can be identified in small vessels and glomerular capillary walls, leading to leukoclastic vasculitis in the skin and membranoproliferative glomerulonephritis in the kidney. Other HCV-associated entities include porphyria cutanea tarda, lichen planus, necrolytic acral erythema, membranous glomerulonephritis, diabetic nephropathy, B-cell non-Hodgkin lymphomas, insulin resistance, sialadenitis, sicca syndrome, and autoimmune thyroiditis. This paper highlights the histomorphologic features of these processes, which are typically characterized by chronic inflammation, immune complex deposition, and immunoproliferative disease in the affected organ.
[Mh] Termos MeSH primário: Doenças Autoimunes/imunologia
Hepatite C/complicações
Hepatite C/imunologia
Doenças do Complexo Imune/imunologia
Transtornos Imunoproliferativos/imunologia
[Mh] Termos MeSH secundário: Doenças Autoimunes/etiologia
Doenças Autoimunes/patologia
Crioglobulinemia/complicações
Crioglobulinemia/imunologia
Crioglobulinemia/patologia
Glomerulonefrite Membranoproliferativa/etiologia
Glomerulonefrite Membranoproliferativa/imunologia
Glomerulonefrite Membranoproliferativa/patologia
Hepacivirus/imunologia
Hepatite C/patologia
Seres Humanos
Doenças do Complexo Imune/etiologia
Doenças do Complexo Imune/mortalidade
Transtornos Imunoproliferativos/etiologia
Transtornos Imunoproliferativos/patologia
Vasculite/etiologia
Vasculite/imunologia
[Pt] Tipo de publicação:JOURNAL ARTICLE; REVIEW
[Em] Mês de entrada:1301
[Cu] Atualização por classe:170220
[Lr] Data última revisão:
170220
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:120825
[St] Status:MEDLINE
[do] DOI:10.1155/2012/740138



página 1 de 9 ir para página                      
   


Refinar a pesquisa
  Base de dados : MEDLINE Formulário avançado   

    Pesquisar no campo  
1  
2
3
 
           



Search engine: iAH v2.6 powered by WWWISIS

BIREME/OPAS/OMS - Centro Latino-Americano e do Caribe de Informação em Ciências da Saúde